MIRA INFORM REPORT
|
Report Date : |
23.02.2013 |
IDENTIFICATION DETAILS
|
Name : |
CADILA PHARMACEUTICALS LIMITED |
|
|
|
|
Registered
Office : |
Cadila Corporate Campus, Sarkhej Dhokla Road, Ahmedabad – 380008,
Gujarat |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2012 |
|
|
|
|
Date of
Incorporation : |
28.02.1991 |
|
|
|
|
Com. Reg. No.: |
04-015132 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.800.000 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24231GJ1991PLC015132 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
AHMC0038ID |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACC6251E |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical
Products. |
|
|
|
|
No. of Employees
: |
Information denied by the
management. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (55) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 9270000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track
record. Financial position of the company appears to be sound. Trade
relations are reported as trustworthy. Business is active. Payments are
reported to be regular and as per commitments. The company can be considered good for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
India is developing into an open-market economy, yet traces
of its past autarkic policies remain. Economic liberalization, including industrial
deregulation, privatization of state-owned enterprises, and reduced controls on
foreign trade and investment, began in the early 1990s and has served to
accelerate the country's growth, which has averaged more than 7% per year since
1997. India's diverse economy encompasses traditional village farming, modern
agriculture, handicrafts, a wide range of modern industries, and a multitude of
services. Slightly more than half of the work force is in agriculture, but
services are the major source of economic growth, accounting for more than half
of India's output, with only one-third of its labor force. India has
capitalized on its large educated English-speaking population to become a major
exporter of information technology services and software workers. In 2010, the
Indian economy rebounded robustly from the global financial crisis - in large
part because of strong domestic demand - and growth exceeded 8% year-on-year in
real terms. However, India's economic growth in 2011 slowed because of persistently
high inflation and interest rates and little progress on economic reforms. High
international crude prices have exacerbated the government's fuel subsidy
expenditures contributing to a higher fiscal deficit, and a worsening current
account deficit. Little economic reform took place in 2011 largely due to
corruption scandals that have slowed legislative work. India's medium-term
growth outlook is positive due to a young population and corresponding low
dependency ratio, healthy savings and investment rates, and increasing
integration into the global economy. India has many long-term challenges that
it has not yet fully addressed, including widespread poverty, inadequate
physical and social infrastructure, limited non-agricultural employment
opportunities, scarce access to quality basic and higher education, and
accommodating rural-to-urban migration.
|
Source
: CIA |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
CARE |
|
Rating |
Short Terms Bank Loan Rating = A2 |
|
Rating Explanation |
Strong degree of safety and very low
credit risk |
|
Date |
October 2011 to March 2012 |
|
Rating Agency Name |
CARE |
|
Rating |
Long Terms Bank Loan Rating = BBB+ |
|
Rating Explanation |
Moderate degree of safety and moderate credit risk. |
|
Date |
October 2011 to March 2012 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DECLINED BY
|
Name : |
Mr. Vipul Gandhi |
|
Designation : |
Assistant Manager in Finance |
|
Contact No.: |
91-2718-225002 |
|
Date : |
20.02.2013 |
LOCATIONS
|
Registered / Corporate Office
: |
Cadila Corporate Campus, Sarkhej
- |
|
Tel. No.: |
91-2718-225001 (15 Lines) |
|
Fax No.: |
91-2718-225039 |
|
E-Mail : |
secretarial@cadilapharma.co.in rmankodi@cadilapharma.co.in
(For materials details) purchase@cadilapharma.com |
|
Website: |
|
|
Area : |
44 acres |
|
Location : |
Owned |
|
|
|
|
Factory 1: |
Dholka – Manufacturing Plant Survey No. 1389, Trasad Road,
Dholka, Ahmedabad – 387810, Gujarat, India |
|
Tel. No: |
91-79-23421841/83/84/
3422006/7/8/9/10 |
|
Fax No: |
91-79-23420315 / 3421220 |
|
Area: |
50000 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 2: |
Chemical SBU 294, GIDC Estate, Ankleshwar, Gujarat, India |
|
Tel. No: |
91-2646-223846 / 252626 / 251519 |
|
Fax No: |
91-2646-250051 |
|
|
|
|
Factory 3: |
CHPL – Factory / Karnavati
Engineering Limited Survey No. 342, Nani Kadi,
Taluka Kadi, District Mehsana, North
Gujarat, |
|
Tel. No: |
91-2764-262463 / 242037 / 242194
/ 241464-65 |
|
Fax No: |
91-2764-242223 / 242608 |
|
Location : |
Owned |
|
|
|
|
Factory 4: |
Chemicals SBU Factory Plot No. 274, GIDC Industrial Estate, Ankleshwar, |
|
Tel. No: |
91-2646-223846 / 252626 / 251519 |
|
Fax No: |
91-2646-250051 |
|
Area: |
174557 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 5: |
Tissu Culture Lab 756, Prakruti Farm, Hirapur
Chowkdi, Hirapur, Ahmedabad, Gujarat, India |
|
Tel. No: |
91-79-3855260/3855495/496 |
|
Location : |
Owned |
|
|
|
|
Factory 6: |
Cadila Pharmaceuticals Limited, Jammu Industrial Growth Centre, Samba – 184121, District Jammu, Jammu
and Kashmir, India |
|
Tel. No: |
91-1923-241113 / 241114 / 241115 |
|
Fax No: |
91-1923-246744 |
DIRECTORS
AS ON 28.09.2012
|
Name : |
Dr. Rajiv Indravadan Modi |
|
Designation : |
Managing Director |
|
Address : |
13, Sanjiv Building, New Sharda Mandir
Road, Paldi, Ahmedabad – 380007,
Gujarat, India |
|
Date of Birth/Age : |
09.05.1960 |
|
Qualification : |
Ph. D. in
Biological Science |
|
Date of Appointment : |
01.07.2010 |
|
Din No.: |
01394558 |
|
|
|
|
Name : |
Prof. Atul Bipinbhai Tandon |
|
Designation : |
Director |
|
Address : |
A/43, Royal Orchid, Corporate
Road, Opposite Prahlad Nagar Gardens, Prahlad Nagar, Ahmedabad – 380015,
Gujarat, India |
|
Date of Birth/Age : |
03.01.1948 |
|
Date of Appointment : |
04.07.2003 |
|
Din No.: |
00165667 |
|
|
|
|
Name : |
Mrs. Monika Garware Modi |
|
Designation : |
Director |
|
Address : |
13, Sanjiv Building, New Sharda
Mandir Road, Paldi, Ahmedabad – 380
007, Gujarat, India |
|
Date of Birth/Age : |
04.06.1963 |
|
Date of Appointment : |
15.12.1995 |
|
Din No.: |
00143400 |
|
|
|
|
Name : |
Mr. Chinubhai Ramanlal Shah |
|
Designation : |
Director |
|
Address : |
402, Heritage Cresent, |
|
Date of Birth/Age : |
04.06.1937 |
|
Date of Appointment : |
31.03.2001 |
|
Din No.: |
00558310 |
|
|
|
|
Name : |
Prof. Pradip Navin Khandwalla |
|
Designation : |
Director |
|
Address : |
B/101, |
|
Date of Birth/Age : |
18.02.1940 |
|
Date of Appointment : |
14.09.2007 |
|
Din No.: |
00064643 |
|
|
|
|
Name : |
Mrs. Shilaben Indravadan Modi |
|
Designation : |
Director |
|
Address : |
13, Sanjiv Baug, New |
|
Date of Birth/Age : |
09.12.1931 |
|
Qualification : |
Matriculate |
|
Date of Appointment : |
16.12.1995 |
|
Din No.: |
01976356 |
|
|
|
|
Name : |
Mr. Sanjay Sinha |
|
Designation : |
Director |
|
Address : |
A/ 31, Orchid Woods, Opposite
Vodafone House, Prahlad Nagar, Corporate Road, Ahmedabad – 380015, Gujarat,
India |
|
Date of Birth/Age : |
01.11.1958 |
|
Date of Appointment : |
29.09.2012 |
|
Din No.: |
03627342 |
|
|
|
|
Name : |
Mr. Daya Nand Khurana |
|
Designation : |
Director |
|
Address : |
288, Vasant Enclave, Vasant Vihar, New Delhi-110057, India |
|
Date of Birth/Age : |
15.05.1935 |
|
Date of Appointment : |
04.07.2003 |
|
Din No.: |
00020601 |
KEY EXECUTIVES
|
Name : |
Mr. Shreyas Kunjvuhari Parikh |
|
Designation : |
Company Secretary |
|
Address : |
B 001, Aakasheep Anne, Near
Shreyas Railway Crossing, Amba Wadi, Ahmedabad – 380 006, |
|
Date of Birth/Age : |
12.08.1957 |
|
Date of Appointment : |
22.02.2008 |
|
Pan No.: |
AEIPP6513R |
|
|
|
|
Name : |
Mr. A Banergee |
|
Designation : |
President Finance |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 28.09.2012
|
Names of Shareholders |
|
No. of Shares |
|
Indravadan A Modi |
|
7999990 |
|
Shilaben I Modi |
|
7999990 |
|
I. A. Modi |
|
59460955 |
|
I. A. Modi (HUF) |
|
10 |
|
Shilaben I Modi |
|
13333 |
|
R. I. Modi |
|
4525712 |
|
I. A. Modi |
|
10 |
|
|
|
|
|
TOTAL
|
|
80000000 |
AS ON 28.09.2012
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Bodies
corporate |
|
80.00 |
|
Directors
or relatives of directors |
|
20.00 |
|
TOTAL |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical
Products. |
||||||||
|
|
|
||||||||
|
Products : |
|
PRODUCTION STATUS (AS ON 31.03.2011)
|
Particulars |
Unit |
Installed
Capacity |
Actual
Production |
|
Tablets |
Nos in million |
14913 |
6116 |
|
Capsules |
Nos in million |
1124 |
300 |
|
Injections |
Kilo Litres |
298 |
216 |
|
Liquids |
Kilo Litres |
10376 |
2071 |
|
Ophthalmic |
Kilo Litres |
0 |
24 |
|
Ointment |
M.T |
0 |
6 |
|
Dry powder injections |
M.T |
10 |
5 |
|
Granules and dry syrups |
M.T |
220 |
1 |
|
Bulk drugs |
M.T |
979 |
1069 |
|
Tissue cultures |
Nos in million |
10 |
10 |
NOTES:
1. As the Industrial
licensing in respect of Drugs and Pharmaceuticals produced by the Company has been
waived, the particulars of licensed capacity are not stated.
2. The installed
capacity is taken on 2 shift working, as Certified by Management.
3. Production
includes production under Loan License arrangement.
GENERAL INFORMATION
|
No. of Employees : |
Information denied by the
management. |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Bankers : |
|
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Facilities : |
|
||||||||||||||||||
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Financial
Institution : |
Department of Biotechnology, Block 2, CGO Complex, Lodhi Road, New
Delhi-110003, India |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address : |
‘Heritage’, 3rd Floor,
Near Gujarat Vidhyapith, Off Ashram Road, Ahmedabad – 380 014, Gujarat, India |
|
Tel. No.: |
91-79-27582542/ 27582543/
266073100 |
|
Fax No.: |
91-79-27582551 |
|
E-Mail : |
|
|
PAN No: |
AABFD7919A |
|
|
|
|
Joint Venture : |
|
|
|
|
|
Subsidiaries : |
|
|
|
|
|
Other Related Parties : |
|
CAPITAL STRUCTURE
AS ON 31.03.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
80000000 |
Equity Shares |
Rs.10/- each |
Rs.800.000 Millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
800.000 |
800.000 |
800.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1519.643 |
1427.297 |
1332.124 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
2319.643 |
2227.297 |
2132.124 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
4128.851 |
3732.411 |
3754.357 |
|
|
2] Unsecured Loans |
888.708 |
761.579 |
697.619 |
|
|
TOTAL BORROWING |
5017.559 |
4493.990 |
4451.976 |
|
|
DEFERRED TAX LIABILITIES |
506.055 |
490.447 |
462.131 |
|
|
|
|
|
|
|
|
TOTAL |
7843.257 |
7211.734 |
7046.231 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
3473.051 |
3415.718 |
3382.072 |
|
|
Capital work-in-progress |
517.145 |
444.522 |
102.845 |
|
|
|
|
|
|
|
|
INVESTMENT |
1308.584 |
1197.025 |
1138.500 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
1535.482
|
1506.732 |
1148.883
|
|
|
Sundry Debtors |
2299.033
|
1781.776 |
1601.648
|
|
|
Cash & Bank Balances |
168.657
|
201.900 |
274.876
|
|
|
Other Current Assets |
117.118
|
116.818 |
0.000
|
|
|
Loans & Advances |
1538.761
|
1089.302 |
992.624
|
|
Total
Current Assets |
5659.051
|
4696.528 |
4018.031 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
1407.434
|
1022.431 |
1050.234
|
|
|
Other Current Liabilities |
1602.556
|
1464.797 |
493.928
|
|
|
Provisions |
104.584
|
54.831 |
51.055
|
|
Total
Current Liabilities |
3114.574
|
2542.059 |
1595.217
|
|
|
Net Current Assets |
2544.477
|
2154.469 |
2422.814
|
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
7843.257 |
7211.734 |
7046.231 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
9180.544 |
7816.194 |
6478.223 |
|
|
|
Other Income |
115.540 |
84.339 |
250.545 |
|
|
|
TOTAL (A) |
9296.084 |
7900.533 |
6728.768 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of materials consumed |
3127.037 |
2935.607 |
|
|
|
|
Purchases of stock-in-trade |
650.190 |
530.257 |
|
|
|
|
Employee benefit expense |
1485.235 |
1199.865 |
|
|
|
|
Other expenses |
2580.769 |
2415.274 |
6056.171 |
|
|
|
Exceptional items |
404.260 |
253.960 |
|
|
|
|
Changes in
inventories of finished goods, work-in-progress and stock-in-trade |
(14.338) |
(278.820) |
|
|
|
|
TOTAL (B) |
8233.153 |
7056.143 |
6056.171 |
|
|
|
|
|
|
|
|
Less |
PROFIT
/ (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
1062.931 |
844.390 |
672.597 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
609.876 |
444.627 |
424.465 |
|
|
|
|
|
|
|
|
|
|
PROFIT
/ (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
453.055 |
399.763 |
248.132 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
255.268 |
242.856 |
221.698 |
|
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
BEFORE TAX (E-F) (G) |
197.787 |
156.907 |
26.434 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
55.932 |
61.734 |
8.705 |
|
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
AFTER TAX (G-H) (I) |
141.855 |
95.173 |
17.729 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
1272.946 |
1177.773 |
1160.044 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
1414.801 |
1272.946 |
1177.773 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
2927.473 |
NA |
NA |
|
|
|
Royal Income |
12.042 |
NA |
NA |
|
|
TOTAL EARNINGS |
2939.515 |
NA |
NA |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
|
237.146 |
149.845 |
|
|
|
Research material |
|
4.674 |
3.306 |
|
|
|
Stores and spares |
|
16.410 |
4.335 |
|
|
|
Capital goods |
|
140.428 |
116.428 |
|
|
|
Packing material |
|
4.212 |
1.173 |
|
|
TOTAL IMPORTS |
336.261 |
402.870 |
275.087 |
|
|
|
|
|
|
|
|
|
|
Earnings /
(Loss) Per Share (Rs.) |
1.77 |
1.19 |
0.22 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
PAT / Total Income |
(%) |
1.53
|
1.20 |
0.26
|
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
2.15
|
2.00 |
0.41
|
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
2.17
|
1.93 |
0.35
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.09
|
0.07 |
0.01
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
3.50
|
3.15 |
2.84
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.82
|
1.85 |
2.52
|
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by
Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact person |
Yes |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
Yes |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
PAN of Proprietor/Partner/Director, if available |
No |
|
32] |
Date
of Birth of Proprietor/Partner/Director, if available |
Yes |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
Yes |
|
HIGH COURT OF GUJARAT STAMP NUMBER
(SPL.C.A) NO. 17405 OF 2012 |
|||||||||||||
|
Status: PENDING
CCIN No: 001022201217405 Last Listing Date: 15/01/2013 Coram: - ADDITIONAL
REGISTRAR ( JUDICIAL) |
|||||||||||||
|
S.NO. |
NAME OF THE
PETITIONER |
ADVOCATE ON
RECORD |
|||||||||||
|
1 |
RAPTAKOS BRETT
AND COMPANY LIMITED |
MR DAKSHESH
MEHTA for: Petitioner(s) |
|||||||||||
|
|
|
|
|||||||||||
|
S.NO. |
NAME OF THE
RESPONDANT |
ADVOCATE ON
RECORD |
|||||||||||
|
1 |
INTELLECTUAL
PROPERTY APPELLATE BOARD |
|
|||||||||||
|
2 |
CADILA
PHARMACEUTICALS LTD |
|
|||||||||||
|
3 |
ASSISTANT
REGISTRAR OF TRADE MARKS |
|
|||||||||||
|
Presented On : 29/12/2012 Registered On : 29/12/2012 Bench Category : SINGLE BENCH District : AHMEDABAD Case Originated From: THROUGH ADVOCATE Listed : 0 times Stage Name : OFFICE OBJECTION
(FILING STAGE) Office Objection Filing Stage: WHETHER INDEX-CUM-CHRONOLOGY OF DOCUMNETS AND
EVENTS FILED Filing Stage: WHETHER PROPER & FULL COURT FEE IS PAID Filing Stage: WHETHER PAGING IS DONE Filing Stage: WHETHER COPIES ARE LEGIBLE AND WHETHER TYPED
COPIES OF HAND WRITTEN ANNEXURES FILED Filing Stage: WHETHER COPIES ARE TRUE COPIES SO SIGNED BY
ADVOCATE Classification: SJ - NON-SERVICE
- TRADE MARKS ACT, 1999 Act: TRADE UNIONS ACT, 1926 Office Details |
|||||||||||||
|
S. No |
Filing Date |
Document Name |
Advocate Name |
Court Fee on
Document |
Document Details |
||||||||
|
1 |
29/12/2012 |
VAKALATNAMA |
MR DAKSHESH
MEHTA ADVOCATE |
5 |
MR DAKSHESH
MEHTA:1 |
||||||||
|
2 |
29/12/2012 |
MEMO OF APPEAL/PETITION/SUIT |
MR DAKSHESH
MEHTA ADVOCATE |
50 |
MR DAKSHESH
MEHTA:1 |
||||||||
|
Court
Proceedings |
|||||||||||||
|
S. No. |
Notified Date |
Court Code |
Board Sr. No. |
Stage |
Action |
Coram |
|||||||
|
1 |
15/01/2013 |
51 |
-- |
OFFICE OBJECTION
(FILING STAGE) |
NEXT DATE |
ADDITIONAL REGISTRAR (JUDICIAL) |
|||||||
REVIEW OF
OPERATIONS:
During the year,
the net sales increased to Rs.9180.540 Millions from Rs. 7816.190 Millions of
previous year, registering a growth of about 17%. Profit before tax (PBT) improved
to Rs. 197.790 Millions and Profit after tax (PAT) to Rs. 141.860 Millions in
the current year as against PBT of Rs. 156.910 Millions and PAT of Rs. 95.170
Millions of the previous year.
The Company
decided to expand its geographical reach the world over, both in API and
Formulations. As a result, this year the Company has export sales of
Rs.2927.470 Millions as against Rs.2108.070 Millions in the previous year,
registering a substantial growth of about 39%.
The Company is
committed to introduce new products / molecules with its R and D efforts in the
coming years and achieve substantial growth in sales as well as profitability.
|
Unsecured Loan |
As
on 31.03.2012 [Rs.
in Millions] |
As
on 31.03.2011 [Rs.
in Millions] |
|
Public Deposits |
7.242 |
3.818 |
|
Loans and Advances From Related Parties |
562.023 |
410.191 |
|
Other Loans and Advances |
319.443 (B) |
347.570 (C) |
|
TOTAL
|
888.708 |
761.579 |
|
NOTE: (B) From Others [ Deptt.
of Science and Technology]* * Loan under Pharmaceutical Research and Development Programme. (C) From Others [
Deptt. of Science and Technology]* * Loan under Pharmaceutical Research and Development Programme. |
||
BANKERS CHARGES REPORT
AS PER REGISTRY
|
This form is for |
Creation of
charge |
|
Corporate
identity number of the company |
U24231GJ1991PLC015132 |
|
Name of the
company |
CADILA
PHARMACEUTICALS LIMITED |
|
Address of the registered
office or of the principal place of
business in |
Cadila Corporate Campus, Sarkhej
- |
|
Type of charge |
Book Debts Movable Property
[not being pledge] Floating Charge |
|
Particular of
charge holder |
Bank of Baroda , Corporate
Financial Services Branch, 1st Floor, BOB Towers, Opposite Law
Garden, Ellis Bridge, Ahmedabad-380009, Gujarat, India Email: corahm@bankofindia.com |
|
Nature of
description of the instrument creating or modifying the charge |
Agreement of
Supplemental Hypothecation of Plant & Machineries & Currents Assets
dated 17/10/2012 for the Fresh Term Loan-V of Rs. 50 Crores granted by Bank of
Baroda, CFS Branch, Ahmedabad. |
|
Date of
instrument Creating the charge |
17.10.2012 |
|
Amount secured by
the charge |
Rs.500.000
Millions |
|
Brief particulars
of the principal terms an conditions and extent and operation of the charge |
Rate of Interest @2% above Base
Rate i.e. 12.50% p.a. (Floating) at present payable with monthly rests. Terms of Repayment As per sanction
letter. Margin @16.71% Extent and Operation of the charge First pari passu
charge on Plant & Machineries of the Company to be shared with term
lenders and Second pari passu charge on the Current Assets of the Company to
be shared with term lenders. |
|
Short particulars
of the property charged |
All movable Plant
& Machineries of the company more particularly. All current
assets of the company more particularly. |
FIXED ASSETS:
- Freehold Land
- Leasehold
Land
- Building
- Plant and
Machinery
- Furniture and
Fixture
- Office
Equipments
- Vehicles
- Live Stock
PRESS RELEASE:
CADILA
PHARMACEUTICALS SECURES WELLCOME TRUST AWARD
WELLCOME TRUST
SUPPORTS CADILA PHARMACEUTICALS’ PREVENTIVE APPROACH TOWARDS COMBAT CARDIO
VASCULAR DISEASES
Ahmedabad, 29 November, 2010 – Ahmedabad based Pharma major Cadila
Pharmaceuticals Limited has received a prestigious Wellcome Trust Award under
the new R&D for Affordable Healthcare in India initiative to support a
phase III clinical trial of PolycapTM, a combination pill to reduce the risk of
Cardiovascular diseases.
Cardio Vascular Diseases (CVD), predominantly heart disease and stroke, account
for around 30% of all deaths around the world. The PolycapTM offers a primary
prevention strategy to individuals who are at high risk for these illnesses.
PolycapTM comprises three blood pressure reducing agents, including a diuretic
and a beta blocker, together with a cholesterol-lowering
statin. All of the agents have been chosen based on the evidence of their
reducing cardiovascular risk and generic drug status.
The combination pill has already been tested in over 2000 volunteers across 50
centers in India as part of The Indian PolycapTM Study (TIPS) published in the
Lancet in 2009. Results from that phase II trial found that use of the drug
reduces the risk of coronary heart disease by 62% and stroke by 48%.
Speaking of the award, Mr. Indravadan Modi, Chairman of Cadila
Pharmaceuticals said, “We are delighted that our innovative product has gained
recognition by the UK’s leading biomedical foundation, the Wellcome Trust. This
award endorses our efforts in providing research-based revolutionary products
in the cardio care segment.”
The Wellcome Trust award will support the study of at least 5,000 individuals
with no previous history of heart attack or stroke. The placebo-controlled
trial will recruit men over the age of 55 and women over 60 that have been
identified as being at increased risk of CVD through a questionnaire based on
family history and lifestyle factors. The investigators will assess whether
taking PolycapTM for a period of five years can cut the risk of CVD, by
monitoring the incidence of death due to heart attack, non-fatal heart attack,
and non-fatal stroke.
Dr Nick Dunster, Senior Business Analyst at the Wellcome Trust commented:
“Cadila Pharmaceuticals has already reported positive results from previous
clinical trials and we look forward to seeing how PolycapTM performs in this
larger phase III trial. CVD is a global problem, so a drug that can cut the
risk for susceptible individuals has the potential to make a huge impact on
human health the world over, not just in India.”
ABOUTCADILA PHARMACEUTICALS LIMITED.
Cadila Pharmaceuticals Limited. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. It is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the World map with the development of Polycap - a novel and world’s first drug combination for prevention of Cardiovascular Heart Disease.
CPL Biologicals is a newly formed company evolved from a joint venture by Cadila Pharmaceuticals Ltd and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals. In addition, CPL Biologicals will establish manufacturing facilities in India and develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws, regulations
or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.43 |
|
|
1 |
Rs.83.20 |
|
Euro |
1 |
Rs.71.91 |
INFORMATION DETAILS
|
Information
Gathered by : |
SVA |
|
|
|
|
Report Prepared
by : |
TPT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
4 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
YES |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
55 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.